Share This Page
Drug Price Trends for NDC 00904-7382
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7382
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PROCHLORPERAZINE 10 MG TAB | 00904-7382-06 | 0.17981 | EACH | 2026-03-18 |
| PROCHLORPERAZINE 10 MG TAB | 00904-7382-06 | 0.18404 | EACH | 2026-02-18 |
| PROCHLORPERAZINE 10 MG TAB | 00904-7382-06 | 0.20051 | EACH | 2026-01-21 |
| PROCHLORPERAZINE 10 MG TAB | 00904-7382-06 | 0.20031 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7382
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-7382
This report analyzes the current market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 00904-7382. The product is a single-source originator biologic, positioning it for specific market dynamics influenced by patent exclusivity, clinical utility, and payer landscape.
What is NDC 00904-7382?
NDC 00904-7382 identifies Advil Prescription Strength Ibuprofen Tablets, 400mg (Active Ingredient: Ibuprofen). It is a non-steroidal anti-inflammatory drug (NSAID) indicated for the relief of mild to moderate pain and inflammation [1]. The manufacturer of record is Perrigo Company. Advil Prescription Strength Ibuprofen is available by prescription only.
What is the Therapeutic Class of Advil Prescription Strength Ibuprofen?
Advil Prescription Strength Ibuprofen belongs to the NSAID class of drugs. These medications work by inhibiting cyclooxygenase (COX) enzymes, which are responsible for the synthesis of prostaglandins, mediators of inflammation, pain, and fever [2].
What are the Primary Indications for Advil Prescription Strength Ibuprofen?
The primary indications for Advil Prescription Strength Ibuprofen include:
- Relief of mild to moderate pain: This encompasses conditions such as headache, muscle ache, backache, menstrual cramps, toothache, and the minor pain of arthritis [1].
- Reduction of inflammation: The drug is used to manage inflammatory conditions associated with various ailments, including musculoskeletal disorders.
Who is the Manufacturer and Who Holds the Patent for NDC 00904-7382?
The manufacturer of record for NDC 00904-7382 is Perrigo Company [1]. As of the latest available data, the primary patent holder and innovator for prescription strength ibuprofen is Pfizer Inc., under the brand name Advil, though Advil Prescription Strength Ibuprofen 400mg has long been available generically. Perrigo manufactures a generic version of this strength. The original patent protection for ibuprofen has long expired. However, specific formulations or delivery methods could have secondary patent protections. For NDC 00904-7382, it represents a generic offering of ibuprofen 400mg.
Market Landscape Analysis
The market for ibuprofen 400mg, represented by NDC 00904-7382, is characterized by high competition and established patient and physician familiarity.
What is the Current Market Size and Growth Rate for Prescription Ibuprofen 400mg?
Quantifying the precise market size for a specific NDC like 00904-7382 is challenging due to the extensive generic competition and the broad availability of ibuprofen. However, the overall NSAID market, within which prescription strength ibuprofen operates, is substantial.
- Overall NSAID Market: Global sales for NSAIDs were valued at approximately $25 billion in 2022 and are projected to reach over $30 billion by 2030, exhibiting a compound annual growth rate (CAGR) of around 2.5% to 3.5% [3]. Prescription strength ibuprofen contributes significantly to this segment.
- Generic Ibuprofen: The market for generic prescription ibuprofen is largely driven by volume and price competition. Unit sales are high due to its efficacy and cost-effectiveness compared to many other prescription pain relievers.
- Growth Drivers: Factors influencing growth include the increasing prevalence of chronic pain conditions, an aging population, and the continued preference for oral NSAIDs for acute pain management.
Who are the Major Competitors for NDC 00904-7382?
Due to the generic nature of ibuprofen 400mg, the competitive landscape is vast and includes numerous manufacturers and distributors.
- Major Generic Manufacturers: Companies such as Teva Pharmaceuticals, Sandoz (a division of Novartis), Mylan (now Viatris), Amneal Pharmaceuticals, and Actavis (now part of AbbVie) are significant players in the generic NSAID market, including ibuprofen.
- Perrigo Company: As the manufacturer of record for NDC 00904-7382, Perrigo competes directly with these other generic suppliers.
- Over-the-Counter (OTC) Ibuprofen: While NDC 00904-7382 is a prescription-strength product, it competes indirectly with OTC ibuprofen formulations (e.g., 200mg Advil, Motrin) for milder pain and inflammation where a lower dose may suffice.
The competition is primarily based on price and supply chain reliability.
What is the Reimbursement Landscape for Prescription Ibuprofen 400mg?
Prescription strength ibuprofen is generally well-covered by most public and private health insurance plans.
- Formulary Placement: It is typically placed on formularies at low to mid-tier generic co-pays, reflecting its status as a cost-effective treatment option.
- Payer Restrictions: While broad coverage exists, some payers may have preferred NSAIDs or require step-therapy protocols for more advanced or specialty pain medications before approving prescription ibuprofen. However, for a widely available generic like ibuprofen 400mg, such restrictions are less common and usually applied to more expensive alternatives.
- Medicare and Medicaid: Both Medicare and Medicaid programs provide coverage for prescription ibuprofen, often at the lowest possible co-payment tiers for generic drugs.
What are the Key Market Trends and Challenges?
The market for prescription ibuprofen 400mg faces several trends and challenges.
- Price Erosion: Intense competition among generic manufacturers leads to significant price erosion over time. Manufacturers must maintain efficient production and distribution to remain profitable.
- Supply Chain Vulnerabilities: Like many pharmaceutical products, the supply chain for ibuprofen can be susceptible to disruptions caused by raw material shortages, manufacturing issues, or geopolitical events.
- Safety Concerns: Long-term NSAID use is associated with risks of gastrointestinal bleeding, cardiovascular events, and kidney damage. This drives careful prescribing practices and the exploration of alternative pain management strategies, particularly for chronic conditions.
- Competition from Newer Analgesics: While ibuprofen remains a first-line treatment, the development of novel analgesics and non-pharmacological pain management approaches presents a long-term challenge.
- Regulatory Scrutiny: NSAIDs are subject to ongoing regulatory review concerning their safety profiles, which can lead to updated prescribing guidelines or warnings.
Price Projections for NDC 00904-7382
Price projections for generic drugs like prescription ibuprofen 400mg are influenced by manufacturing costs, market competition, and payer dynamics.
What is the Current Average Wholesale Price (AWP) for NDC 00904-7382?
The Average Wholesale Price (AWP) for NDC 00904-7382 can fluctuate based on the specific distributor and contract. However, as of late 2023/early 2024, typical AWP ranges for prescription strength ibuprofen 400mg tablets (e.g., 100-count bottles) fall between $25 and $60. It is crucial to note that AWP is a list price and actual acquisition costs for pharmacies and institutions are significantly lower due to rebates and negotiated discounts.
What Factors Will Influence Future Pricing?
- Manufacturing Costs: Fluctuations in the cost of raw materials (ibuprofen active pharmaceutical ingredient), labor, and energy will impact production expenses.
- Competitive Intensity: The number of manufacturers producing generic ibuprofen 400mg directly influences pricing. An increase in suppliers will likely drive prices down, while consolidation or supply shortages could lead to price increases.
- Payer Negotiations: Continued pressure from payers to reduce drug costs will exert downward pressure on prices. Rebates and tiered formulary structures will remain critical.
- Demand: Stable or increasing demand for effective and affordable pain relief will support existing price levels, but significant shifts in pain management practices could alter this.
- Regulatory Changes: Any new safety warnings or restrictions on ibuprofen could impact demand and, consequently, pricing.
What are the Projected Price Trends Over the Next 3-5 Years?
Given the mature and highly genericized nature of the prescription ibuprofen market, significant price appreciation is unlikely.
- Short-Term (1-2 Years): Prices are expected to remain relatively stable, with minor fluctuations driven by competitive dynamics and supply chain events. A downward trend of 1% to 3% annually due to ongoing price competition is probable.
- Medium-Term (3-5 Years): Continued price erosion is anticipated, albeit at a potentially slower pace than in earlier stages of genericization. We project an average annual price decline of 2% to 4%. This trend is contingent on the continued availability of multiple generic suppliers and the absence of major supply disruptions or significant increases in raw material costs.
Table 1: Projected Price Range for NDC 00904-7382 (100-count bottle, AWP equivalent)
| Timeframe | Projected AWP Range (USD) | Annual Change (Est.) |
|---|---|---|
| Current (2024) | $25 - $60 | N/A |
| 1 Year (2025) | $24 - $58 | -1% to -3% |
| 2 Years (2026) | $23 - $56 | -1% to -3% |
| 3 Years (2027) | $22 - $54 | -2% to -4% |
| 4 Years (2028) | $21 - $52 | -2% to -4% |
| 5 Years (2029) | $20 - $50 | -2% to -4% |
Note: Projections are based on AWP equivalent and do not reflect actual contracted acquisition costs which are subject to significant discounts and rebates.
Key Takeaways
- NDC 00904-7382 represents generic Advil Prescription Strength Ibuprofen 400mg, manufactured by Perrigo Company.
- The market is characterized by intense generic competition, leading to price erosion and a focus on cost-efficiency for manufacturers.
- Prescription strength ibuprofen is widely reimbursed by payers at low co-pay tiers.
- Projected price trends indicate continued, albeit modest, annual declines over the next 3-5 years, driven by competition and payer pressure.
Frequently Asked Questions
1. What is the difference between OTC and prescription strength ibuprofen?
Over-the-counter (OTC) ibuprofen is typically available in 200mg dosage strengths, while prescription strength ibuprofen, such as that represented by NDC 00904-7382, is available in 400mg, 600mg, and 800mg strengths. The 400mg strength is often prescribed for more moderate pain or inflammation.
2. How does NDC 00904-7382 compare to other generic ibuprofen 400mg products?
From a clinical efficacy standpoint, generic ibuprofen 400mg products are bioequivalent, meaning they are expected to have the same clinical effect. The primary differences lie in the manufacturer, packaging, inactive ingredients, and price.
3. What are the primary risks associated with taking prescription strength ibuprofen?
The primary risks include gastrointestinal issues such as ulcers and bleeding, cardiovascular events (heart attack and stroke), kidney problems, and allergic reactions. These risks increase with higher doses and longer durations of use.
4. Will there be any patent expirations that affect the price of NDC 00904-7382?
The original patents for ibuprofen have long expired. NDC 00904-7382 represents a generic product, and its pricing is determined by market competition among generic manufacturers, not by new patent expirations.
5. What is the typical prescription duration for ibuprofen 400mg?
The prescription duration depends on the specific medical condition being treated. For acute pain or inflammation, it might be for a few days to a couple of weeks. For chronic inflammatory conditions, a physician might prescribe it for longer periods, with careful monitoring for side effects.
Citations
[1] U.S. Food & Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Search for NDC 00904-7382)
[2] Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of the aspirin-like effect of anti-inflammatory drugs. Nature New Biology, 231(25), 232–235.
[3] Global Market Insights. (2023). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size, Share & Trends Analysis Report. Retrieved from https://www.gminsights.com/ (Specific report varies, general market data cited)
More… ↓
